OSU6162 in Bipolar Depression (OBID) (OBID)

OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)

An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in inpatients with bipolar depression. The study will consist of 9 visits and 1 safety visit.

Inpatients with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.

Study Overview

• Status: Recruiting
• Conditions: Bipolar Depression
• Intervention / Treatment: Drug: OSU6162

• Study Type: Interventional
• Enrollment (Estimated): 22
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Elias Eriksson, Professor; Phone Number: + 46 709 555055; Email: elias.eriksson@neuro.gu.se
• Study Contact Backup: Name: Steinn Steingrimsson, MD, PhD; Phone Number: + 46 722 448372; Email: steinn.steingrimsson@vgregion.se

Study Locations

• Sweden
  • Gothenburg, Sweden, SE 405 30
    • Recruiting
    • Sahlgrenska University Hospital/Östra
    • Contact: Michael Ioannou, MD; Phone Number: +46 70 082 38 20; Email: michael.ioannou@vgregion.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed informed consent
2. Voluntary admission to the psychiatric ward prior or directly after the screening point
3. Age: 18-65 on the day of screening
4. Meeting DSM-5 criteria for a depressive episode in Bipolar Disorder type I or type II, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
5. Displaying a sum score of ≥10 on the Bech 6-item subscale of the Hamilton Depression rating Scale.
6. Treatment with a stable dose of a mood stabilizer since at least 4 weeks before screening: lithium s-conc> 0,45 mmol/L; >lamotrigine dose 100 mg/d; >valproate dose > 900 mg/d, >carbamazepine concentration >20 mmol/L
7. In female patients of childbearing potential: negative result of a pregnancy test and a method of contraception with a failure rate of less than 1 %. Women of childbearing potential must, for inclusion, use a highly efficient method of contraception, i.e. a method with a failure rate of less than 1% (e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomy in partner).
8. Male patients must agree to use condoms during the study and for 2 weeks after the end of the study/last dose of IMP, unless their partner is using a highly efficient method of contraception, as described above.

Exclusion Criteria:

1. Ongoing compulsory care.
2. Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
3. Previously diagnosed or meeting MINI criteria at interview for obsessive-compulsive disorder or post-traumatic stress disorder.
4. A previous diagnosis of a personality disorder, autism, ADHD, or intellectual disability.
5. A history of substance/alcohol abuse within 2 years prior to screening.
6. Any other previously diagnosed or suspected CNS disorder that according to the investigator renders the patient unsuitable for participation in the trial (such as dementia, brain injury, and epilepsy).
7. Young Mania Rating Scale (YMRS) total score of >12 at screening or at any time during the trial.
8. Any somatic illness that according to the investigator renders the patient unsuitable for participation in the trial.
9. Any signs or symptoms of somatic illness resulting from assessment of vital signs, physical examination, clinical laboratory tests or 12- lead ECG that according to the investigator renders the patient unsuitable for participation for safety reasons, including a QTc-time on ECG exceeding 450 ms in men and 460 ms in women.
10. Any factor that according to the investigator renders it unlikely that the patient will comply with the instructions regarding treatment, visits etc.
11. Any change in medication (including dosage) of an antidepressant drug or a mood stabiliser within 4 weeks prior to screening or at any time during the trial.
12. Ongoing treatment with potent cytochrome P450 enzyme inhibitors (e.g., bupropion, fluvoxamin, ketoconazol, itraconazole, telitromycin, clarithromycin, protease inhibitors, quinidine, and terbinafine).
13. Ongoing treatment with drugs displaying a narrow therapeutic window - with the exception of lithium - where either reduced or increased serum levels are potentially harmful (including but not limited to warfarin, other anticoagulants, digoxin. other antiarrythmics, anticonvulsants when prescribed for treatment of epilepsy but not when prescribed for bipolar disorder, cyclosporine, and immunosuppressants).
14. Ongoing treatment with drugs with dopaminergic synapses as primary site of action (e.g., antipsychotics, bupropion, central stimulants, and drugs for Parkinson's disease).
15. No observed beneficial effect of treatment and a symptom severity that by the investigator's assessment would render continued participation unethical.
16. Previous intake of OSU6162.
17. Current participation in another clinical trial.
18. Nursing women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: OSU6162; Coated tablet, flexible dosing	Drug: OSU6162; OSU6162

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at endpoint [Day 60].	Endpoint at 60 days treatment

Collaborators and Investigators

• Sponsor: Göteborg University
• Collaborators: Arvid Carlsson Research AB

Study record dates

Study Major Dates

• Study Start (Actual): October 25, 2021
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): May 31, 2027

Study Registration Dates

• First Submitted: November 8, 2021
• First Submitted That Met QC Criteria: March 24, 2022
• First Posted (Actual): March 25, 2022

Study Record Updates

• Last Update Posted (Actual): October 3, 2023
• Last Update Submitted That Met QC Criteria: October 2, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Bipolar and Related Disorders; Depression; Depressive Disorder; Bipolar Disorder
• Other Study ID Numbers: EudraCT number: 2020-001980-95; 2020-001980-95 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No